--- title: "Petros Pharmaceuticals (PTPI) news: delisting and offering" url: "https://aibio.space/companies/petros-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PTPI delisting and offering news: Nasdaq panel moves to delist Petros Pharmaceuticals, trading to shift to OTC. Petros Pharmaceuticals, Inc." --- PTPI Petros Pharmaceuticals, Inc. OTC · United States # Petros Pharmaceuticals (PTPI) news PTPI delisting and offering news Distress · 2026-09-30 ## [Petros Pharmaceuticals assigns all assets to creditors and halts operations](https://aibio.space/news/petros-pharmaceuticals-assigns-all-assets-creditors-halts-operations/) Petros Pharmaceuticals assigned all of its assets to PT Liquidation, LLC for the benefit of creditors on September 30, 2026, and says it has ceased substantially all operations. The executive chairman and two directors resigned the same day, and the Series A preferred stock must be redeemed immediately. ## Latest Petros Pharmaceuticals news 1. 2026-06-18 Company Updates [Petros names Robert Weinstein chief accounting officer](https://aibio.space/news/petros-names-robert-weinstein-chief-accounting-officer/) Petros appointed Robert Weinstein as chief accounting officer and principal financial officer on June 18, 2026, the day it separated Mitchell Arnold from his finance roles. 2. 2026-06-05 Company Updates [Petros grants 7,000,000 restricted shares to directors and officers](https://aibio.space/news/petros-grants-7-000-000-restricted-shares-directors-officers/) The board approved restricted share awards on June 5, 2026, to the chairman, two directors and the president and chief commercial officer. 3. 2025-05-21 Listings [Nasdaq panel moves to delist Petros Pharmaceuticals, trading to shift to OTC](https://aibio.space/news/nasdaq-panel-moves-delist-petros-pharmaceuticals-trading-shift-otc/) A Nasdaq Hearings Panel has decided to delist Petros, with trading suspended at the open on May 22, 2025, on four grounds that include equity and bid-price rules and concern over the February 2025 public offering. Petros will ask the Listing Council to review the decision. 4. 2025-02-19 Financings [Petros Pharmaceuticals prices $9.6 million offering of stock and warrants at $0.24](https://aibio.space/news/petros-pharmaceuticals-prices-9-6-million-offering-stock-warrants-0-24/) Petros is selling about 40,000,000 shares, or pre-funded warrants in their place, at $0.24 for about $9.6 million gross. Dawson James Securities, Inc. is the placement agent, paid 8% of the gross proceeds, and the warrants cannot be exercised until stockholders approve them. ## Petros Pharmaceuticals at a glance - **Ticker**: PTPI - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $3.5 million ### Related companies - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) NASDAQ: ATOS - [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) NASDAQ: SBFM - [Gossamer Bio](https://aibio.space/companies/gossamer-bio/) NASDAQ: GOSS - [MabCure](https://aibio.space/companies/mabcure/) OTC: MBCI - [Lotus Pharmaceuticals](https://aibio.space/companies/lotus-pharmaceuticals/) OTC: LTUS - [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) NASDAQ: ABUS - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) NASDAQ: AGIO - [Acrivon Therapeutics](https://aibio.space/companies/acrivon-therapeutics/) NASDAQ: ACRV ### Also on OTC - [POSITRON CORP](https://aibio.space/companies/positron/) POSC - [Global Innovative Platforms](https://aibio.space/companies/global-innovative-platforms/) GIPL - [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) VICP - [ENvue Medical](https://aibio.space/companies/envue-medical/) FEED - [Vincerx Pharma](https://aibio.space/companies/vincerx-pharma/) VINC - [BIOTRICITY INC.](https://aibio.space/companies/biotricity/) BTCY ## What Petros Pharmaceuticals does Petros Pharmaceuticals, Inc. describes itself as working toward becoming a leading innovator in the self-care market, through expanded access to nonprescription pharmaceuticals. It discontinued sales of Stendra, a PDE-5 inhibitor for erectile dysfunction licensed from Vivus, Inc., to wholesalers in December 2024 and no longer commercializes Stendra from March 2025. Its subsidiaries Metuchen Pharmaceuticals, Timm Medical Technologies and Pos-T-Vac completed an assignment for the benefit of creditors in June 2025, transferring their assets to a third-party assignee. Petros is developing a proprietary integrated technology platform that supports the switch of prescription products to over-the-counter status. The platform has a software-as-a-service component for pharmaceutical companies and a potential Software as a Medical Device consumer interface. The platform is in early development and is anchored in the FDA's rule for nonprescription drug products with an additional condition for nonprescription use. The company expects its primary revenue to come from licensing fees. | Product or program | What it is | Stage | |---|---|---| | Rx-to-OTC SaaS platform | Digital hosting for pharma companies' prescription-to-OTC switch | early development stages | | SaMD consumer interface | Potential software guiding consumer self-selection of OTC products | early development; must comply with FDA governance | | Stendra | PDE-5 inhibitor for erectile dysfunction licensed from Vivus | no longer commercialized since March 2025 | Summarised from the company's [10-K filed Apr 15, 2026](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/tmb-20251231x10k.htm). ## Petros Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$5.1 million](https://www.sec.gov/Archives/edgar/data/1815903/000141057825000579/) | | Research and development | | [$2.6 million](https://www.sec.gov/Archives/edgar/data/1815903/000141057825000579/) | | Net income (loss) | [$1.9 million](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/) | [-$14.3 million](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/) | | Cash from operations | [-$6.7 million](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/) | [-$2.6 million](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/) | | Cash and equivalents | [$5.1 million](https://www.sec.gov/Archives/edgar/data/1815903/000110465926095979/) | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Petros Pharmaceuticals Was Petros Pharmaceuticals delisted? Our latest story on this, dated May 21, 2025: "Nasdaq panel moves to delist Petros Pharmaceuticals, trading to shift to OTC". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-panel-moves-delist-petros-pharmaceuticals-trading-shift-otc/). Has Petros Pharmaceuticals raised money recently? Our latest story on this, dated May 21, 2025: "Nasdaq panel moves to delist Petros Pharmaceuticals, trading to shift to OTC". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-panel-moves-delist-petros-pharmaceuticals-trading-shift-otc/). What is the ticker symbol of Petros Pharmaceuticals? Petros Pharmaceuticals, Inc. trades under the ticker PTPI on OTC. Where is Petros Pharmaceuticals listed? Petros Pharmaceuticals, Inc. is listed on OTC. What is the SEC CIK of Petros Pharmaceuticals? The SEC Central Index Key (CIK) for Petros Pharmaceuticals, Inc. is 1815903. Its filings are on SEC EDGAR. How many shares does Petros Pharmaceuticals have outstanding? 42,372,260 shares as of 2026-08-15, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Petros Pharmaceuticals listed under? Our directory records Petros Pharmaceuticals, Inc. under United States. What does Petros Pharmaceuticals do? Our directory classifies Petros Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Petros Pharmaceuticals? The ISIN recorded for Petros Pharmaceuticals, Inc. is US71678J3086. Does aibio.space cover Petros Pharmaceuticals? aibio.space lists Petros Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Petros Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Petros Pharmaceuticals develop? Petros Pharmaceuticals, Inc. describes itself as working toward becoming a leading innovator in the self-care market, through expanded access to nonprescription pharmaceuticals. It discontinued sales of Stendra, a PDE-5 inhibitor for erectile dysfunction licensed from Vivus, Inc., to wholesalers in December 2024 and no longer commercializes Stendra from March 2025. What is Rx-to-OTC SaaS platform from Petros Pharmaceuticals? Rx-to-OTC SaaS platform: Digital hosting for pharma companies' prescription-to-OTC switch Stage: early development stages. What is SaMD consumer interface from Petros Pharmaceuticals? SaMD consumer interface: Potential software guiding consumer self-selection of OTC products Stage: early development; must comply with FDA governance. Is Petros Pharmaceuticals profitable? Petros Pharmaceuticals, Inc. reported net income of $1.9 million for the fiscal year ended Dec 31, 2025, and used $6.7 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Petros Pharmaceuticals Members talk about Petros Pharmaceuticals (PTPI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Petros Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-09-30 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.03,2.04,5.02). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/tm2626722d1_8k.htm) 2. 2026-04-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/tmb-20251231x10k.htm) 3. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465926037800/tm2533655d2_nt10k.htm) 4. 2025-11-20 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1815903/000135445725001163/xslF25X02/primary_doc.xml) 5. 2025-11-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925108552/tm2530149d1_8k.htm) 6. 2025-09-05 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925087887/tm2524779d1_8k.htm) 7. 2025-05-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925051336/tm2515781d1_8k.htm) 8. 2025-05-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925044240/tm2513449d1_8k.htm) 9. 2025-04-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.03,5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925034283/tm2512195d1_8k.htm) 10. 2025-04-09 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925033391/tm2511732d1_8k.htm) 11. 2025-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1815903/000141057825000579/tmb-20241231x10k.htm) 12. 2025-03-18 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925025104/tm258582d4_def14a.htm) 13. 2025-03-07 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925021794/tm258582d1_pre14a.htm) 14. 2025-02-19 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1815903/000141057825000164/tmb-20240930x424b4.htm) 15. 2025-01-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465925005980/tm254392d1_8k.htm) 16. 2024-12-16 Distress Reported that a debt obligation was accelerated. SEC Form 8-K (Items 2.04,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465924128984/tm2431088d1_8k.htm) 17. 2024-11-21 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1815903/000110465924121603/tm2429163d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:PTPI on TradingView](https://www.tradingview.com/symbols/OTC-PTPI/). ## SEC filings and registration - **SEC name**: Petros Pharmaceuticals, Inc. - **CIK**: 1815903 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PTPI (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036 - **Phone**: 973-242-0005 - **Shares outstanding**: 42,372,260 as of 2026-08-15 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1815903/000110465926112399/tm2626722d1_8k.htm) filed 2026-09-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1815903/000110465926095979/tmb-20260630x10q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/tm2618334d1_8k.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1815903/000110465926071027/tm2616064d1_8k.htm) filed 2026-06-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1815903/000110465926060359/tmb-20260331x10q.htm) filed 2026-05-13 - [10-K](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/tmb-20251231x10k.htm) filed 2026-04-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1815903/000110465926000236/tm261703d1_8k.htm) filed 2026-01-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1815903/000110465925111338/tmb-20250930x10q.htm) filed 2025-11-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001815903), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Petros Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker PTPI, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Petros Pharmaceuticals, Inc. - **Ticker**: PTPI - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US71678J3086 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-PTPI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/petros-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Petros Pharmaceuticals (PTPI) news: delisting and offering", 2026-10-31, https://aibio.space/companies/petros-pharmaceuticals/